Clinical Data Allogene data suggest ‘off-the-shelf’ CAR-T could delay relapse in lymphoma BioPharma DiveInitial results from a high-stakes trial indicate the biotech may have finally found a niche in lymphoma care for a donor-derived cell therapy.Clinical DataOncologyRead full story pharminent April 13, 2026 (Last updated: April 14, 2026) BioPharma Dive Initial results from a high-stakes trial indicate the biotech may have finally found a niche in lymphoma care for a donor-derived cell therapy. Clinical DataOncologyRead full story Post navigation Previous: FDA Reminds More Than 2,200 Sponsors and Researchers to Disclose Trial ResultsNext: Spyre drug for inflammatory bowel disease shows promise in early study Related Stories Clinical Data Novartis hit as Lp(a) drug fails cardio outcomes trial pharminent September 7, 2026 Clinical Data Major trial of Roche Alzheimer’s drug kicks off in Europe pharminent September 7, 2026 Clinical Data AbbVie’s T cell engager delivers survival benefit in Phase 3 multiple myeloma study pharminent September 4, 2026